Home > Insider Trading > Filing (0001209191-19-036289)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1618835	Evofem Biosciences Inc.	EVFM	Investment Advice (6282)	D0

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
914208	Ltd. Invesco	1555 Peachtree Street Ne Suite 1800 Atlanta GA 30309		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-06-10	2,222,222	$4.50	11,812,910	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrants	Disposition	2019-06-10	212,765	$0.00	212,765	$5.20
Common Stock	Right to Purchase	Acquisiton	2019-06-10	555,556	$0.00	555,556	$6.38

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
555,556		2026-02-08	No	4	J	Indirect
555,556			No	4	J	Indirect

Footnotes

Invesco Ltd. is the beneficial owner of 11,812,910 shares of common stock and warrants to purchase 555,556 common shares acquired by its affiliates, Invesco High Income Fund(UK) and Invesco Income Fund(UK).
Pursuant to the Securities Purchase Agreement, Invesco Ltd. agreed to cancel warrants to purchase 212,765 shares of Common Stock.
The warrants were exercisable on the earlier of 08/08/2019, or following the date that the issuance of the warrants was approved by the stockholders of the Issuer.
Invesco Ltd. owned the warrants through its affiliates, Invesco High Income Fund (UK) and Invesco Income Fund (UK).
On June 10, 2019, Invesco Ltd. exercised its right, pursuant to that certain Securities Purchase Agreement between the Issuer, Invesco Ltd., PLD Biopharma, and Woodford Asset Management Limited dated April 10, 2019 (the "Securities Purchase Agreement"), to purchase (i) 2,222,222 shares of common stock at a purchase price of $4.50 per share and (ii) warrants to purchase 555,556 shares of common stock at a purchase price equal to $6.38 per share.
The warrants are exercisable six (6) months following the original issue date.
The warrants expire seven (7) years following the original issue date.